Molecular biology reports · 2026
Association of miR-199a-3p and CDK7 expression with clinicopathological features of breast cancer.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Ibrahim Noralhuda Ayad, Hidayat Hazha Jamal
Аннотация
BACKGROUND: Breast cancer (BC) remains the most common malignancy among women worldwide. miR-199a-3p has been implicated in several cancers, while Cyclin-Dependent Kinase 7 (CDK7) plays a critical role in cell cycle regulation and transcriptional control.
OBJECTIVE: To evaluate the expression profile and diagnostic performance of miR-199a-3p and CDK7 in BC tissues and investigate their associations with clinicopathological characteristics.
METHODS: This study was conducted on 30 paired BC and adjacent normal breast tissue samples collected in Erbil, Iraq. Expression levels of miR-199a-3p and CDK7 were quantified using qRT-PCR. Also, blood samples were collected to estimate CA 15 - 3.
RESULTS: Among 30 BC patients, there was a significant difference in miR-199a-3p expression in tumor tissues compared to paired control tissues (P = 0.0029), with a downregulation of 0.506-fold relative to the control group. In contrast, CDK7 expression did not differ significantly between tumor and control tissues (P = 0.140). The serum CA 15 - 3 levels were considerably higher in BC patients (P < 0.001) and the AUC was 0.754 (95% CI: 0.623-0.867) with a sensitivity of 43.3% and specificity of 96.7% at a threshold value of 25.1 U/mL. miR-199a-3p presented an AUC of 0.720 (95% CI, 0.581-0.839) and CDK7 an AUC of 0.621 (95% CI, 0.467-0.764). The combined miR-199a-3p/CDK7 model showed an AUC of 0.750 (95% CI: 0.619-0.886) with 76.7% sensitivity and 80.0% specificity. The higher CDK7 expression was associated with PR-negative status (P = 0.038).
CONCLUSION: miR-199a-3p may be a possible biomarker for BC diagnosis with considerably low expression and moderate diagnostic efficacy. The combination miR-199a-3p/CDK7 model enhanced diagnostic discrimination, while serum CA 15 - 3 showed good specificity. The relationship of CDK7 with PR status further supports its therapeutic importance.
OBJECTIVE: To evaluate the expression profile and diagnostic performance of miR-199a-3p and CDK7 in BC tissues and investigate their associations with clinicopathological characteristics.
METHODS: This study was conducted on 30 paired BC and adjacent normal breast tissue samples collected in Erbil, Iraq. Expression levels of miR-199a-3p and CDK7 were quantified using qRT-PCR. Also, blood samples were collected to estimate CA 15 - 3.
RESULTS: Among 30 BC patients, there was a significant difference in miR-199a-3p expression in tumor tissues compared to paired control tissues (P = 0.0029), with a downregulation of 0.506-fold relative to the control group. In contrast, CDK7 expression did not differ significantly between tumor and control tissues (P = 0.140). The serum CA 15 - 3 levels were considerably higher in BC patients (P < 0.001) and the AUC was 0.754 (95% CI: 0.623-0.867) with a sensitivity of 43.3% and specificity of 96.7% at a threshold value of 25.1 U/mL. miR-199a-3p presented an AUC of 0.720 (95% CI, 0.581-0.839) and CDK7 an AUC of 0.621 (95% CI, 0.467-0.764). The combined miR-199a-3p/CDK7 model showed an AUC of 0.750 (95% CI: 0.619-0.886) with 76.7% sensitivity and 80.0% specificity. The higher CDK7 expression was associated with PR-negative status (P = 0.038).
CONCLUSION: miR-199a-3p may be a possible biomarker for BC diagnosis with considerably low expression and moderate diagnostic efficacy. The combination miR-199a-3p/CDK7 model enhanced diagnostic discrimination, while serum CA 15 - 3 showed good specificity. The relationship of CDK7 with PR status further supports its therapeutic importance.